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Abstract
The transcription factor nuclear factor κB (NF-κB) rapidly reprograms gene expression in
response to various stimuli, and its activity is regulated by several posttranslational modifications,
including phosphorylation, methylation, and acetylation. The addition of O-linked β-N-
acetylglucosamine (a process known as O-GlcNAcylation) is an abundant posttranslational
modification that is enhanced in conditions such as hyperglycemia and cellular stress. We report
that the NF-κB subunit c-Rel is modified and activated by O-GlcNAcylation. We identified serine
350 as the site of O-GlcNAcylation, which was required for the DNA binding and transactivation
functions of c-Rel. Blocking the O-GlcNAcylation of this residue abrogated c-Rel–mediated
expression of the cytokine-encoding genes IL2, IFNG, and CSF2 in response to T cell receptor
(TCR) activation, whereas increasing the extent of O-GlcNAcylation of cellular proteins enhanced
the expression of these genes. TCR- or tumor necrosis factor (TNF)–induced expression of other
NF-κB target genes, such as NFKBIA (which encodes IκBα) and TNFAIP3 (which encodes A20),
occurred independently of the O-GlcNAcylation of c-Rel. Our findings suggest a stimulus-specific
role for hyperglycemia-induced O-GlcNAcylation of c-Rel in promoting T cell–mediated
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Fig. S1. The NF-κB protein c-Rel is modified by O-GlcNAcylation.
Fig. S2. Coomassie blue staining of immunoprecipitated c-Rel.
Fig. S3. Mutation of the O-GlcNAcylation site of c-Rel does not affect its nuclear translocation.
Fig. S4. Glucose enhances the DNA binding ability of c-Rel, and expression of the S350A mutant c-Rel does not affect the DNA
binding ability of p65.
Fig. S5. IL2, IFNG, and CSF2 are c-Rel–dependent genes.
Fig. S6. Mutant c-Rel does not have a dominant-negative effect on the function of wild-type c-Rel.
Fig. S7. TNF-induced activation of c-Rel is independent of its O-GlcNAcylation.
Author contributions: P.R. conceived the project and designed and performed the experiments; P.M.C. performed the PEG labeling;
D.E.M. and E.C.P. performed the mass spectrometry; P.R., P.M.C., L.C.H.-W., and D.B. analyzed and interpreted the data; and P.R.
and D.B. wrote, and all of the authors edited, the manuscript.
Competing interests: A patent was filed for the targeting of c-Rel O-GlcNAcylation (File No. CIT-6437-P).
NIH Public Access
Author Manuscript
Sci Signal. Author manuscript; available in PMC 2014 June 23.
Published in final edited form as:
Sci Signal. ; 6(290): ra75. doi:10.1126/scisignal.2004097.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
autoimmunity in conditions such as type 1 diabetes by enhancing the production of T helper cell
cytokines.
INTRODUCTION
Nuclear factor κB (NF-κB) is a pleiotropic, evolutionarily conserved transcription factor
family with multiple roles in cell survival, development, apoptosis, immunity, and
inflammatory responses (1). The NF-κB family is composed of five monomers that function
in dimeric pairs: p65 (RelA), RelB, c-Rel, p50 (and its precursor p105), and p52 (and its
precursor p100). NF-κB family members are preformed proteins that reside, in unstimulated
cells, mostly in the cytoplasm bound to inhibitory proteins of the inhibitor of κB (IκB)
family. In general, activation occurs through signal-induced phosphorylation and
proteasome-mediated degradation of IκB, which releases bound NF-κB, enabling its
translocation to the nucleus where it activates transcription (2). Because the NF-κB family
members are preformed proteins, their initial activation and activity is often regulated by
posttranslational modifications rather than by induction of their synthesis. All NF-κB
members are regulated by phosphorylation and ubiquitylation (3, 4). The p105, p100, and
p65 subunits are also regulated by acetylation. Modifications of NF-κB proteins by S-
nitrosylation, oxidation, nitration, and alkylation are also known, although the physiological
roles of the individual modifications remain poorly defined (3).
O-GlcNAc glycosylation (O-GlcNAcylation) is an essential and abundant form of
intracellular posttranslational protein modification. It involves attachment of the
monosaccharide N-acetyl-D-glucosamine (GlcNAc) to serine or threonine residues in nuclear
and cytoplasmic proteins of multicellular eukaryotes (5, 6). O-GlcNAcylation is a dynamic,
reversible process akin to phosphorylation, with the addition and removal of O-GlcNAc
catalyzed by O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA), respectively (6).
Several lines of evidence suggest a reciprocal relationship between O-GlcNAc and
phosphate, which may occupy the same or adjacent serine or threonine residues in proteins
or may occur simultaneously at different sites in a protein (6, 7). O-GlcNAcylation plays an
important role in many key cellular processes, including cell cycle regulation (8, 9),
transcription and translation (6), protein stability and turnover (10), cellular stress (11), and
gene expression (6, 12). Lack of O-GlcNAcylation is embryonically lethal, as is seen in
OGT-deficient mice, and O-GlcNAcylation is essential for T cell function (13, 14).
The extent of O-GlcNAcylation of proteins is increased under hyperglycemic conditions,
and O-GlcNAcylation enhances NF-κB–dependent transcription (15). Both O-
GlcNAcylation and NF-κB activation are associated with experimental and clinical diabetes
(16–19). Growing evidence supports a pivotal role for O-GlcNAcylation in the activation of
NF-κB in B cells and T cells (20). Regulation of the NF-κB subunit p65 by O-
GlcNAcylation has received some attention, with identification of the sites of modification
and of their role in influencing p65 function (21, 22). Although both NF-κB and O-
GlcNAcylation were discovered more than 25 years ago, the role of this posttranslational
modification in regulating NF-κB subunits other than p65 remains largely uncharacterized.
Moreover, relatively few studies have pinpointed the site of modification on proteins or
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established the site-specific functions for O-GlcNAc. So far, less than 10% of the known O-
GlcNAcylated proteins have had their modification sites identified (6).
While studying the glucose dependency of various cell types, we found that a high glucose
concentration selectively promoted the survival of potentially self-reactive T cells by
increasing the expression of several NF-κB–dependent genes that encode antiapoptotic
proteins (23). Because hyperglycemia also enhances the extent of O-GlcNAcylation of
proteins, we examined the O-GlcNAcylation status of all of the NF-κB family proteins in
lymphocytes under hyperglycemic conditions. Here, we showed that c-Rel is the major O-
GlcNAcylated NF-κB subunit in lymphocytes, and that enhancement of its O-
GlcNAcylation increased its transcriptional activity. We identified serine 350 (Ser350) as the
site of O-GlcNAcylation in c-Rel by collision-induced dissociation mass spectrometry (CID-
MS) and CID-MS after BEMAD [β-elimination followed by Michael addition with 2-
aminoethanethiol (2-AET)] derivatization and site-directed mutagenesis. Mutation of Ser350
completely blocked the O-GlcNAcylation of c-Rel, compromising its DNA binding and
transactivation in cells in response to stimulation of the T cell receptor (TCR). Our study
links the physiological functions of c-Rel and O-GlcNAcylation in T cells, and it suggests a
previously unknown and potentially pathologic role of O-GlcNAcylation: promoting
autoimmunity by enhancing the production of cytokines by helper T cells through
modulation of c-Rel function.
RESULTS
The NF-κB protein c-Rel is modified by O-GlcNAcylation
We examined NF-κB proteins in various cellular systems for evidence of increased O-
GlcNAcylation, and we found that c-Rel was a major O-GlcNAcylated NF-κB protein in
both B (Ramos) and T (Jurkat) lymphoblastoid cell lines (Fig. 1A). To enrich the O-
GlcNAcylated pool of proteins, we exposed cells to GlcNAc, a precursor of GlcNAcylation,
and to O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate
(PUGNAc) (24), a potent inhibitor of the enzyme OGA, which catalyzes the cleavage of O-
GlcNAc from serine and threonine residues of modified proteins. Inhibition of OGA
increases the pool of O-GlcNAcylated proteins in cells. We also detected the O-
GlcNAcylation of c-Rel in cells exposed to a pathophysiologically relevant hyperglycemic
concentration of glucose (30 mM), and the addition of PUGNAc further enhanced the extent
of O-GlcNAcylation of c-Rel (Fig. 1B). Under similar conditions, c-Rel was also O-
GlcNAcylated in primary mouse splenocytes (Fig. 1C). As previously reported (15, 20–22),
we also observed the O-GlcNAcylation of the NF-κB protein p65 in primary splenocytes
(Fig. 1C). O-GlcNAcylated c-Rel existed in a complex with p65 in the cytoplasm, as
indicated by their reciprocal coimmunoprecipitation (Fig. 1, C and D). Unlike
phosphorylation, O-GlcNAcylation does not change the electrophoretic mobility of modified
proteins (6). The O-GlcNAcylated band in p65 immunoprecipitates appeared to have a
greater molecular mass than that of p65, suggesting that the coimmunoprecipitated c-Rel had
undergone O-GlcNAcylation (Fig. 1D). Furthermore, after depletion of c-Rel from the
lysates, reimmunoprecipitated p65 failed to show evidence of O-GlcNAcylation (fig. S1A),
suggesting that c-Rel was the major O-GlcNAcylated protein in lymphocytes.
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We also found the O-GlcNAcylation of c-Rel in human peripheral blood mononuclear cells
(PBMCs), as well as in the glucose-dependent mouse T cell line EL4 (Fig. 1E) (23);
however, we did not observe O-GlcNAcylation of endogenous c-Rel in human embryonic
kidney (HEK) 293T cells, an epithelial cell line, or in mouse embryonic fibroblasts (MEFs)
(Fig. 1, E and F), even when global O-GlcNAcylation in these cells was enhanced (fig.
S1B). We found that c-Rel in Jurkat cells bound to the O-GlcNAc–binding lectin wheat
germ agglutinin (WGA), and its reactivity to the lectin increased in the presence of GlcNAc
and PUGNAc (Fig. 1F). Furthermore, a chemoenzymatic method to biotinylate and detect
O-GlcNAcylated proteins showed O-GlcNAcylated c-Rel in Ramos cells and Jurkat cells
(Fig. 1G). We found that both c-Rel and p65 were O-GlcNAcylated in a heterologous
baculoviral expression system when coexpressed with OGT (Fig. 1H). Finally, we
precipitated c-Rel from GlcNAc- and PUGNAc-treated cells with an anti–O-GlcNAc
antibody (Fig. 1I).
c-Rel is O-GlcNAcylated at Ser350 in the Rel inhibitory domain
To identify the stoichiometry of c-Rel O-GlcNAcylation, we used a chemoenzymatic
approach to label O-GlcNAc residues with a 5-kD polyethylene glycol 5000 (PEG 5000)
mass tag (25). This approach increases the molecular mass of the glycoprotein in 5-kD
increments, depending on the number of O-GlcNAc moieties that are attached to the protein.
We found that human c-Rel showed a shift of 5 kD in Jurkat cells and Ramos cells after
treatment with PUGNAc and high concentrations of glucose, which suggests that modified
c-Rel was predominantly mono-O-GlcNAcylated (Fig. 2A). We saw an increased proportion
of O-GlcNAcylated c-Rel in cells in response to 30 mM glucose compared to that in cells
treated with 5 mM glucose, suggesting that the O-GlcNAcylation of c-Rel was both dynamic
and inducible (Fig. 2A). We quantified the stoichiometry of O-GlcNAcylated c-Rel in cells
in 30 mM glucose by densitometry and found that about 20% of the total c-Rel protein was
modified with O-GlcNAc (Fig. 2B).
To map the site of O-GlcNAcylation, we immunoprecipitated endogenous c-Rel from Jurkat
cells or Ramos cells treated with a high concentration of glucose (30 mM) and PUGNAc
(fig. S2), and we analyzed the chymotrypsin digest and the BEMAD-derivatized digests by
nano–liquid chromatography–tandem mass spectrometry (nanoLC-MS/MS). O-GlcNAc
residues are often labile during CID-MS. BEMAD derivatization replaces the labile carbon-
oxygen linkage of the O-GlcNAc modification with a more stable carbon-sulfur linkage that
can be identified by MS. Together, these experiments mapped O-GlcNAcylation to Ser349 or
Ser350 of human c-Rel (Fig. 2, C and D). We separately mutated each of these serines to
alanines, expressed the mutant c-Rel proteins in transfected cells, and examined their O-
GlcNAcylation under hyperglycemic conditions. Unlike endogenous c-Rel, exogenous c-Rel
was O-GlcNAcylated in HEK 293T cells. Although the c-Rel S349A mutant was O-
GlcNAcylated to the same extent as wild-type c-Rel, the S350A mutation completely
blocked O-GlcNAcylation (Fig. 2E). Ser350 in c-Rel is located in its Rel inhibitory domain
(RID) (Fig. 2F) (26). Both Ser349 and Ser350 are also conserved in mouse c-Rel (Fig. 2G).
The location of Ser350 in c-Rel corresponds to the location of the O-GlcNAcylation site in
p65 (Thr352) (21), suggesting conserved accessibility of this region for the enzyme OGT.
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Thus, consistent with the PEG labeling data (Fig. 2A), we identified a single serine residue
in c-Rel, Ser350, as the O-GlcNAcylation site.
OGT is capable of forming complexes with its substrates (27).We found that the lack of O-
GlcNAcylation of the c-Rel S350A mutant was not because of its inability to bind to OGT,
because overexpressed wild-type c-Rel and the S350A c-Rel mutant bound to endogenous
OGT to similar extents (Fig. 2H). Moreover, the S350A mutation did not interfere with the
ability of c-Rel to form dimers, indicating its competence for performing the protein-protein
interactions that are crucial for NF-κB function (Fig. 2I).
Mutation of Ser350 to alanine blocks the O-GlcNAcylation and transactivation of c-Rel but
not its TCR-dependent phosphorylation
To investigate the function of the O-GlcNAcylation of c-Rel, we initially assayed the
transactivation ability of overexpressed c-Rel. We found that a CD28-responsive DNA
element–driven luciferase reporter gave a greater response to c-Rel–induced activation than
did immunoglobulin κB (Ig-κB) or IL12-p40-κB site-driven luciferase reporters (Fig. 3A).
On this basis, we studied c-Rel function by costimulating Jurkat cells with anti-CD3 and
anti-CD28 antibodies. We found that the S350A mutant c-Rel had greatly reduced
transactivation potential compared to that of wild-type c-Rel when increased in abundance
(Fig. 3B) or when cells were costimulated by anti-CD3 and anti-CD28 antibodies (Fig. 3C).
We attempted to study the S350A mutant c-Rel by creating a cell line that constitutively
overexpresses wild-type or mutant c-Rel. But these efforts were plagued by the fact that the
increased amounts of c-Rel in transfected cells led to cell death after a few days, consistent
with previous reports (28, 29). To circumvent this problem, we expressed c-Rel in Jurkat T-
REx cells with a tetracycline-inducible system. We first suppressed endogenous c-Rel
through the lentiviral delivery of a short hairpin RNA (shRNA) that targeted the 3′
noncoding region of c-Rel, which then enabled the cells to tolerate increased amounts of
exogenous c-Rel, and enabled us to analyze the function of the inducibly expressed wild-
type and mutant protein with minimum interference from the endogenous protein. We
achieved about 75% knockdown of endogenous c-Rel abundance (Fig. 3D) and observed a
substantial reduction in c-Rel–dependent interleukin-2 (IL-2) production in response to
stimulation of the cells with phorbol 12-myristate 13-acetate (PMA) and ionomycin (Fig.
3E). We then generated stable cell clones that, under the control of a tetracycline-regulated
promoter, could inducibly express FLAG-tagged wild-type c-Rel or the S350A mutant c-
Rel, which was not subject to O-GlcNAcylation. Addition of the tetracycline analog
doxycycline induced the production of detectable amounts of FLAG-tagged wild-type and
mutant c-Rel proteins in these clones after 20 to 24 hours (Fig. 3F).We analyzed multiple
cell clones to exclude clonal variation and to verify the consistency of inducible c-Rel
production and the responses of the cells to costimulation with anti-CD3 and anti-CD28
antibodies. Consistent with the results of our overexpression experiments, we found that the
doxycycline-induced wild-type c-Rel was O-GlcNAcylated, whereas the S350A mutant c-
Rel protein, although it was present at a similar amount to that of the wild-type protein,
showed a complete lack of O-GlcNAcylation (Fig. 3G).
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On the basis of findings from previous studies, c-Rel Ser350 is not thought to be
phosphorylated (3). We stimulated the phosphorylation of c-Rel by treating cells with anti-
CD3 and anti-CD28 antibodies, conditions that cause an increase in c-Rel abundance (30,
31), as well as the extent of its phosphorylation (32). However, we could not detect any
difference in the overall phosphorylation extent of doxycycline-induced wild-type or mutant
c-Rel proteins when we performed an orthophosphate labeling assay (Fig. 3H).
The S350A mutation compromises the DNA binding ability of c-Rel
To study nuclear translocation, we induced c-Rel protein in Jurkat T-REx cell clones and
stimulated these cells with anti-CD3 and anti-CD28 antibodies. We then prepared and
analyzed cytoplasmic and nuclear extracts of the cells and found comparable translocation
of wild-type and mutant c-Rel proteins into the nucleus (Fig. 4A). We observed similar
results in experiments in which we transiently transfected mouse EL4 T cells with plasmids
encoding wild-type or S350A mutant c-Rel and then stimulated the nuclear translocation of
these proteins by treating the cells with anti-CD3 and anti-CD28 antibodies (fig. S3).
Treatment of the Jurkat T-REx cell clones with PMA and ionomycin, which activates the
same downstream signaling components that are activated in response to costimulation with
anti-CD3 and anti-CD28, also resulted in comparable nuclear translocation of wild-type and
S350A mutant c-Rel (Fig. 4B). As previously reported (30–32), we also observed an
increase in the amounts of c-Rel proteins after stimulation of cells with anti-CD3 and anti-
CD28 or with PMA and ionomycin, and this response occurred in cells expressing either
wild-type or the S350A mutant c-Rel (Figs. 3H and 4, A to C). We also found inducibly
expressed FLAG-tagged O-GlcNAcylated c-Rel in the nuclei of Jurkat cells in response to
costimulation with anti-CD3 and anti-CD28, which was suggestive of a nuclear role for the
modified c-Rel (Fig. 4C).
Because the nuclear translocation of the S350A mutant c-Rel was intact, we next examined
its DNA binding properties in an attempt to account for its compromised transactivation
ability. With an electrophoretic mobility shift assay (EMSA), we observed that nuclear
extracts from cells expressing FLAG-tagged wild-type c-Rel showed enhanced binding to
the CD28RE probe (33) upon costimulation with anti-CD3 and anti-CD28 antibodies (Fig.
4D). The addition of an anti-FLAG antibody to the binding reaction predominantly blocked
DNA-protein binding and led to a supershift in a portion of the complex, implying that
FLAG-tagged c-Rel was bound to the DNA. In contrast, nuclear extracts from cells with the
S350A mutant c-Rel mutant showed substantially less DNA binding upon costimulation
with anti-CD3 and anti-CD28, and they lacked a shifted complex in the presence of the anti-
FLAG antibody, as determined by EMSA experiments (Fig. 4D). We could compete both
wild-type and mutant c-Rel complexes with a 100-fold excess of unlabeled probe. We used
the DNA binding of OCT1, which could be competed with an OCT1 probe, as a control for
the gel shift assays. The observed differences in the DNA binding abilities of wild-type and
S350A mutant c-Rel were not a result of differences in the amount of the relevant proteins in
the nuclear extracts (Fig. 4D, bottom). Mutations in the CD28RE region completely
abolished the binding of the c-Rel protein complexes to the probe, indicating the specificity
of the interaction (Fig. 4E). Similar to the situation in cells expressing the S350A mutant c-
Rel, treatment of cells with 6-diazo-5-oxo-L-norleucine (DON), which inhibits O-
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GlcNAcylation (34), decreased the extent of CD28RE binding in nuclear extracts from cells
expressing wild-type c-Rel upon costimulation with anti-CD3 and anti-CD28 antibodies
(Fig. 4F). Conversely, enhancement of O-GlcNAcylation by treating cells with PUGNAc
(Fig. 4G) or culturing cells with an increased concentration of glucose (fig. S4A)
substantially increased the extent of binding of c-Rel to the CD28RE DNA probe.
Maximal induction of IL2 expression depends on multiple transcription factors, including c-
Rel, p65, activating protein 1 (AP-1), and nuclear factor of activated T cells (NFAT) (35).
To be certain that mutation of the O-GlcNAcylation site of c-Rel specifically affected its
binding to the AT-rich CD28RE region and not to the other, GC-rich NF-κB site in the IL2
promoter, we studied DNA binding with a probe for the p65-binding region (IL2-κB) of the
IL2 promoter (36). Anti-CD3– and anti-CD28–inducible IL2-κB–DNA–protein complexes
were formed from samples of cells expressing either wild-type or mutant c-Rel, with a
modest increase in the extent of DNA binding of the latter (Fig. 4H). An anti-FLAG
antibody did not supershift these DNA-bound complexes, indicating the absence of FLAG–
c-Rel in these complexes (Fig. 4H). This result also demonstrates that TCR activation
efficiently stimulates both wild-type and mutant c-Rel–expressing cell lines. To further
validate that the S350A mutant c-Rel had a defect in its DNA binding ability, we performed
an in vitro oligonucleotide pulldown assay. Consistent with the gel shift assays, we found
that the S350A mutant c-Rel showed markedly reduced binding to a biotinylated CD28RE
probe compared to that of the wild-type c-Rel (Fig. 4I). In addition, we found that the
binding of p65 to the CD28RE probe occurred similarly in cell lines expressing either wild-
type or mutant c-Rel (fig. S4B).
The O-GlcNAcylation of c-Rel induces the expression of a subclass of TCR-induced genes
TCR signaling mediates autoimmune T cell responses in hyperglycemic conditions such as
diabetes (37). We studied the costimulation of T cells with anti-CD3 and anti-CD28
antibodies, conditions that mimic the TCR activation that induces the expression of several
c-Rel–dependent genes, including IL2, IFNG, and CSF2 (26, 38, 39). In experiments with c-
Rel–deficient T cells, we confirmed that these genes were indeed dependent on c-Rel for
their expression (fig. S5A). We observed substantially potentiated anti-CD3– and anti-
CD28–induced expression of IL2 and CSF2 in Jurkat cells after exposure to PUGNAc
compared to that in cells that were not treated with PUGNAc (Fig. 5, A and B),
substantiating the requirement of O-GlcNAcylation for c-Rel transactivation (Fig. 3, B and
C).
Consistent with the impaired DNA binding of the S350A mutant c-Rel (Fig. 4, D, E, and I),
mutation of the O-GlcNAcylation site of c-Rel markedly suppressed anti-CD3– and anti-
CD28–induced expression of IL2, CSF2, and IFNG (Fig. 5, C to E). However, other NF-
κB–dependent genes, including NFKBIA and TNFAIP3, which have potential c-Rel–binding
sites in their promoters (40) but are mainly induced by p65, were expressed to similar
extents in cells containing wild-type or mutant c-Rel (Fig. 5, F and G). This finding
indicates that TCR signaling and NF-κB activation are intact in cells expressing the S350A
mutant c-Rel. PUGNAc substantially potentiated the expression of c-Rel–dependent genes
only in wild-type cells, emphasizing the role of O-GlcNAcylation in this transactivation
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process (Fig. 5, C to E). Further confirming the effect of PUGNAc, streptozotocin (STZ),
another OGA inhibitor that promotes O-GlcNAcylation (Fig. 5H) (41), and high glucose
(fig. S5B) also enhanced the anti-CD3– and anti-CD28–induced, c-Rel–dependent
expression of IL2, CSF2, or both. The S350A mutant c-Rel did not appear to exhibit any
dominant-negative effect, because it did not affect the basal expression of several c-Rel–
dependent genes (fig. S6, A to D).
Neither the S350A mutation of c-Rel nor PUGNAc-enhanced O-GlcNAcylation alters TNF-
induced gene expression
TNF stimulates the phosphorylation of c-Rel and induces its transactivation function (42).
We studied the role of the enhanced O-GlcNAcylation of c-Rel and the effect of the S350A
mutation on TNF-induced, NF-κB–dependent gene expression. Neither the S350A mutation
nor PUGNAc affected the TNF-induced expression of NFKBIA or TNFAIP3 (Fig. 6, A and
B). In addition, TNF did not enhance the expression of IL2 or CSF2 in these cells (Fig. 6, C
and D). Consistent with these observations, we found that PUGNAc, which enhances the
general extent of O-GlcNAcylation within the cell, had no effect on the TNF-dependent
nuclear translocation of c-Rel, although it decreased the amount of p65 that translocated to
the nucleus in response to TNF (Fig. 6E). Further, TNF did not stimulate the translocation of
O-GlcNAcylated c-Rel to the nucleus (Fig. 6F and fig. S7). These results suggest that TNF
induces the expression of NFKBIA and TNFAIP3 independently of c-Rel in Jurkat T cells or
that the induction of these genes in response to TNF is mediated by c-Rel that is not
GlcNAcylated. Because p65 takes a dominant and redundant role in NF-κB–dependent gene
expression in response to TNF, the ability to independently define TNF-induced, c-Rel–
dependent genes remains a challenge. Thus, c-Rel and its O-GlcNAcylation are stimulus-
specific and seem relevant in TCR-induced, but not TNF-induced, expression of selected
genes (Fig. 6G).
DISCUSSION
Here, we identified a single site of O-GlcNAcylation, Ser350, in the NF-κB protein c-Rel. O-
GlcNAcylation substantially stimulated c-Rel–dependent transactivation and was required
for the expression of several genes after TCR costimulation. We delineated the mechanism
by which c-Rel was regulated by O-GlcNAc modification, showing that Ser350 was required
for the binding of c-Rel to DNA, and also how the extent of O-GlcNAcylation of c-Rel
modulated this process.
Our results show that O-GlcNAcylation of c-Rel is required for TCR-induced expression of
IL2, CSF2, and IFNG. All of these genes contain the CD28RE in their promoters (33),
suggesting a critical role of O-GlcNAcylated c-Rel in mediating CD28RE-dependent
transcription. We did not observe any effect of mutating the O-GlcNAcylation site of c-Rel
or of treating cells with PUGNAc on TCR- or TNF-induced expression of TNFAIP3 and
NFKBIA, genes that are thought to contain c-Rel–binding sites in their promoters (40);
however, it has not been shown unambiguously that these genes are indeed dependent on c-
Rel. Additionally, we found that increased O-GlcNAcylation did not affect the TNF-
dependent nuclear translocation of c-Rel, and conversely, TNF had no substantial effect on
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glucose- or GlcNAc-induced O-GlcNAcylation of c-Rel (Fig. 6F and fig. S7). These
observations suggest that TNF might stimulate the transactivation of c-Rel independently of
its O-GlcNAcylation status. We found that TCR stimulation mediated transactivation of c-
Rel through both O-GlcNAcylation–dependent and O-GlcNAcylation–independent
pathways. Although both the TCR and TNF signaling stimulated the nuclear translocation of
c-Rel, only TCR signaling resulted in the presence of O-GlcNAcylated c-Rel in the nucleus.
This might depend on a TCRdependent cofactor that binds to O-GlcNAcylated c-Rel in the
cytoplasm to facilitate its nuclear translocation. Alternatively, c-Rel may become O-
GlcNAcylated in the nucleus after TCR activation. These results suggest a stimulus-specific
role of O-GlcNAcylation in modulating c-Rel function.
Both OGT- and c-Rel–deficient mice show impaired T helper 1 (TH1)–type responses (14,
43). Inhibition of OGT in Jurkat cells causes impaired anti-CD3– and anti-CD28–dependent
NF-κB activation and IL2 expression (20). These findings suggest an overlap in the function
of O-GlcNAcylation and NF-κB. Golks et al. (20) showed that OGT is critical for the
activation of NF-κB in lymphocytes, and they suggested that p65 was the O-GlcNAcylated
NF-κB protein. Our results show that c-Rel is the major O-GlcNAcylated protein in
lymphocytes and that it exists in a complex with p65 (Fig. 1, C and D). In addition to p65-
bound c-Rel, it is possible that the c-Rel homodimer and a c-Rel–p50 heterodimer are also
O-GlcNAcylated. This could be tested in cells devoid of p65 or p50.
The CD28RE region exhibits high-affinity binding to c-Rel homodimers. Complexes
containing p65 and p50 also bind, albeit weakly, to this region (44, 45). We found that the
binding of p65 to the CD28RE region occurred independently of c-Rel binding (fig. S4B),
suggesting the presence of distinct c-Rel– and p65-containing complexes bound to this
region. Thus, although both c-Rel and p65 are capable of binding to the CD28RE region, it
seems likely that only c-Rel homodimers or c-Rel–p50 heterodimers are involved in
CD28RE-dependent transactivation. Consistent with this notion, anti-CD3– and anti-CD28–
induced transcription of IL2 occurs independently of p65 (46). Because we found that O-
GlcNAcylated c-Rel was mostly in the cytoplasm in complex with p65, it is plausible that
modified c-Rel may sequester p65 in the cytoplasm and thus dampen p65-dependent
transcription. Supporting this notion, we found that the extent of DNA binding by p65 was
modestly enhanced in cells with a mutant c-Rel, and that the PUGNAc-mediated increase in
O-GlcNAcylation decreased the extent of the TNF-dependent nuclear translocation of p65
(Figs. 4H and 6E). Consistent with our data, others have also reported that PUGNAc
decreases the p65-mediated induction of some NF-κB–dependent genes (47). In contrast,
high concentrations of glucose and glucosamine increase the extent of p65 O-GlcNAcylation
and enhance the NF-κB–dependent transcription of target genes (15, 21). The differences
between these studies may be due to the use of different cell types or different types of NF-
κB–activating stimuli, which may dictate the functional outcome of NF-κB O-
GlcNAcylation.
An increase in the extent of O-GlcNAcylation of p65 decreases its affinity for IκB and
facilitates the nuclear translocation of p65 (21). However, we did not see any marked
differences in the nuclear translocation of either wild-type c-Rel or the S350A mutant c-Rel,
making it unlikely that O-GlcNAcylation modifies the binding of c-Rel to IκB. Ser350 is
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well-separated from the Rel homology domain (RHD), which is required for DNA binding
and dimerization (44, 48). Whether O-GlcNAcylation of Ser350 causes any structural
alteration of the DNA binding domain and how this might enhance the DNA binding
property of c-Rel are important questions to be addressed in future studies. O-
GlcNAcylation facilitates the DNA binding of other transcription factors, such as Pdx-1 (49)
and YY1 (50). Similarly, our results suggest that O-GlcNAcylation regulates the NF-κB
protein c-Rel by facilitating its DNA binding and subsequent transactivation. We also
reported a similar role for methylation of p65 in promoting its DNA binding property (51).
In addition, acetylation of p65 enhances its affinity for DNA (52). These findings suggest
that posttranslational modifications play a major role in inducing NF-κB–DNA interactions.
Our discovery of the O-GlcNAcylation of c-Rel adds yet another layer of complexity to the
regulation of NF-κB. c-Rel is crucial for lymphocyte function and has important roles in T
cell–mediated immune responses and autoimmunity. Similarly, the process of O-
GlcNAcylation is also important for T cell function. Our study reveals important crosstalk
between sugar metabolism, NF-κB signaling, and T cell function that have implications for
autoimmunity, diabetes, and cancer, conditions in which dysregulation of both NF-κB
signaling and O-GlcNAcylation are implicated. c-Rel is particularly important for the
development and proliferation of immunosuppressive regulatory T cells (Tregs) (53).
Understanding how hyperglycemia and the O-GlcNAcylation of c-Rel affect Tregs and
autoimmunity is an important area of future research, and our investigations in this direction
are in progress. High glucose–induced O-GlcNAcylation of c-Rel and its enhanced
activation might act as a positive regulator of autoimmune diabetes. The increased
expression of the c-Rel–dependent genes IL2 and IFNG may enhance TH1 cell function and
cell-mediated cytotoxicity, accelerating the destruction of pancreatic β cells. Therefore,
targeting the O-GlcNAcylation of c-Rel may prove to be an effective tool to suppress
autoreactive T cells and thereby suppress autoimmunity.
MATERIALS AND METHODS
Reagents and antibodies
Glucose, GlcNAc, STZ, DON, PMA, ionomycin, blasticidin, doxycycline, and polyinosinic-
polycytidylic acid [poly(I:C)] were purchased from Sigma. Zeocin was obtained from
Invivogen. PUGNAc was from Toronto Research Chemicals. Recombinant TNF protein was
purchased from PeproTech. [32P]Orthophosphate and [γ-32P]adenosine 5′-triphosphate
(ATP) were obtained from PerkinElmer Radiochemicals. The IL-2 ELISA kit and antibodies
against mouse CD3 (145-2C11) and CD28 (37.51) were from BioLegend. Antibodies
against human CD3 (OKT3) and CD28 (clone 28.2) were obtained from eBioscience.
Antibodies against c-Rel, p65, SP1, OGT, β-actin, PLC-γ, and lamin were from Santa Cruz
Biotechnology. The anti-FLAG antibody was from Sigma. The anti–O-GlcNAc antibodies
RL2 and CTD 110.6 were from Abcam and Covance, respectively.
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Cells
Jurkat, Jurkat T-REx, Ramos, EL4,MEFs, and HEK 293T cells were grown as previously
described (23). Human PBMCs were purchased from AllCells. The tetracycline-inducible
Jurkat T-REx cells were from Invitrogen.
Mice
c-Rel–deficient mice were provided by H.-C. Liou (Weill Medical College of Cornell
University, New York). C57BL/6 mice were from a colony maintained in-house. Mice were
housed and handled in accordance with the National Institutes of Health (NIH) guidelines
under protocols approved by the Institutional Animal Care and Use Committee. All mice
used in this study were 6 to 10 weeks old, unless otherwise indicated.
Plasmids
The complementary DNAs (cDNAs) encoding human c-Rel and its mutants were cloned
into the pCMX vector, which encodes a myc tag, for transient expression in transfected
cells. The S349A and S350A mutants of c-Rel were generated by PCR-based site-directed
mutagenesis. For inducible expression experiments, cDNAs encoding wild-type and mutant
c-Rel containing the FLAG tag were cloned into the pcDNA4 vector (Invitrogen). For
baculoviral expression, cDNAs encoding c-Rel, p65, and OGT were cloned into the vector
pVL1393 (AB Vector).
Orthophosphate labeling
Cellular phosphorylation assays were performed as described previously (54). Briefly,
Jurkat T-REx cells (75 × 106) were treated with doxycycline to induce expression of the
vectors encoding wild-type and mutant c-Rel, starved for 90 min in phosphate-free medium,
and stimulated with anti-CD3 and anti-CD28 antibodies for 3 hours in the presence of
radioactive orthophosphate (0.2 mCi/ml). Cells were harvested, washed with phosphate-free
medium, and lysed. FLAG-tagged c-Rel was immunoprecipitated with an anti-FLAG
antibody, samples were transferred onto membranes, and phosphate incorporation was
assessed by autoradiography.
In vitro chemoenzymatic O-GlcNAc labeling assay
Jurkat or Ramos cells (30 × 106) were treated for 8 hours with 4 mM GlcNAc and 100 µM
PUGNAc. Cells were lysed in a buffer containing 20 mM Hepes (pH 7.9) and 1% SDS.
Proteins were precipitated with methanol/chloroform/water, and labeling reactions were
performed with the Click-IT O-GlcNAc enzymatic labeling system (Invitrogen) according to
the manufacturer’s instructions. Biotin-labeled samples were precipitated with methanol/
chloroform/water, resuspended in buffer containing 50 mM tris-HCl (pH 8.0) and 1% SDS,
and analyzed by Western blotting with a streptavidin–horseradish peroxidase conjugate.
WGA binding assay
Jurkat cells (30 × 106) and MEFs (10 × 106) were cultured overnight in RPMI medium
containing 5 mM glucose with or without 4 mM GlcNAc and 100 µM PUGNAc. Cells were
lysed in lysis buffer [50 mM Hepes (pH 7.9), 150 mM NaCl, 1% Triton X-100, 50 µM
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PUGNAc, and EDTA-free protease inhibitor cocktail]. The lysate was precleared with
protein A/G beads (Santa Cruz Biotechnology) and then incubated with succinylated WGA
(Vector Labs) for 4 hours at 4°C. WGA also binds to sialic acid, and we used succinylated
WGA to limit its binding to sialic acid and increase its specificity for O-GlcNAc. The
immunoprecipitate was resolved by SDS–polyacrylamide gel electrophoresis, and we
performed Western blotting analysis to detect c-Rel (and SP1 as a control) with specific
antibodies.
Baculoviral expression
Baculovirus was produced by transfecting Sf9 insect cells with the pVL1393 vector
encoding the gene of interest with Lipofectamine reagent (Invitrogen). For co-infections,
High Five insect cells were infected with OGT-expressing virus and either c-Rel– or p65-
expressing viruses. Cells were harvested 60 hours after infection and lysed on ice for 30 min
in lysis buffer [11 mM sodium phosphate (pH 7.4), 150 mM NaCl, 0.1% SDS, 0.5% sodium
deoxycholate, 1% Triton X-100, 50 µM PUGNAc, and 1× complete protease inhibitor
cocktail]. Proteins were immunoprecipitated from the lysates and were detected by Western
blotting analysis with an anti–O-GlcNAc antibody (RL2).
In vitro PEG labeling
Jurkat or Ramos cells (10 × 106) were cultured overnight in RPMI medium without glucose.
Cells were treated for 3 hours with 5 or 30 mM glucose and 100 µM PUGNAc and then
lysed by boiling in buffer containing 1% SDS and complete protease inhibitor cocktail
(Roche), and 100 µg of total protein was chemoenzymatically labeled with a 5-kD PEG
mass tag as described previously (25). The labeled lysates were resolved on an 8%
polyacrylamide gel and analyzed by Western blotting. The stoichiometry of O-
GlcNAcylation was determined by taking the ratio of the densitometric value for the PEG–c-
Rel band and dividing it by the sum of the values for the bands corresponding to PEG–c-Rel
and c-Rel.
Mass spectrometry
Jurkat or Ramos cells (4.5 × 108) were cultured overnight in medium containing 5 mM
glucose. Cells were stimulated for 3 hours with 30 mM glucose and 100 µM PUGNAc,
lysed, subjected to immunoprecipitation with an anti–c-Rel antibody, and resolved on a 4 to
12% bis-tris gel in Mops buffer. The band corresponding to c-Rel was excised, manually
digested with chymotrypsin, and analyzed by nanoLC-MS with collision-induced
dissociation (CID) and electron-transfer dissociation (ETD) fragmentation; data were
analyzed as previously described, but with modifications (7). Peptides were separated with a
120-min gradient, and duplicate analyses were performed on an LTQ Orbitrap XL for
accurate mass determination of precursor ions. A portion of the digested peptides was
subjected to BEMAD (55). After 2 hours at 50°C, the reaction was quenched with acetic
acid, and organic solvents were removed by vacuum centrifugation. The sample was
analyzed by nanoLC-MS on an LTQ Orbitrap XL as described earlier. Data were searched
with Mascot software, allowing for the possibility that peptides were modified by the
BEMAD reagent 2-AET at serines or threonines.
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shRNAs and lentiviral transduction
shRNAs specific for the 3′ noncoding region of human c-Rel and for LacZ (as a nonspecific
control) in a microRNA-155–based expression cassette were synthesized and then amplified
by PCR with primers containing restriction sites. Primers used for the c-Rel shRNA
expression cassette were as follows: CTGGAGGCTTGCTGAAGGCTGTATGCTG-
(TTCGCTATGTCCAAAGTTGTA)-gttttggccactgactgac-
(TACAACTTGACATAGCGAA)-
CAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCCA.
Primers used for the LacZ shRNA expression cassette were as follows:
CTGGAGGCTTGCTGAAGGCTGTATGCTG-(TACATCGGGCAAATAATATCG)-
gttttggccactgactgac-(CGATATTATGCCCGATGTA)-
CAGGACACAAGGCCTGTTACTAGCACTCACATGGAACAAATGGCCCA. The 5′
and 3′ linker sequences are represented in bold uppercase letters, the loop is in lowercase
italics, and the shRNA sequence is underlined inside parentheses. These cassettes were
cloned into the pHAGE6 lentiviral vector, and viruses were produced by transfecting HEK
293T cells as described previously (56). To select transduced cells, cDNA encoding the
extracellular domain of human CD271 was placed downstream of the shRNA cassette and
was separated by an internal ribosome entry site (IRES) sequence. Virus was concentrated
100-fold by ultracentrifugation and resuspended in RPMI medium, and 50 µl of virus was
used to infect 200 × 103 Jurkat cells per well in six-well plates in the presence of polybrene
(5 µg/ml). Cells were spun at 1200g for 90 min at 30°C to facilitate viral adherence to the
cell surface, supernatants were discarded, and cells were cultured in fresh medium. Cells
were analyzed for shRNA-mediated knockdown of c-Rel 72 to 96 hours after infection.
Magnetic-activated cell sorting and fluorescence-activated cell sorting
Jurkat cells transduced with lentivirus expressing c-Rel–specific shRNA were selected on
the basis of their cell-surface expression of CD271 by magnetic sorting with anti-CD271
microbeads (Miltenyi Biotec) according to the manufacturer’s instructions. Cells were
blocked with Fc block reagent (anti-mouse CD16 and CD32 antibodies, BD Biosciences),
and CD271 expression was confirmed by fluorescence-activated cell sorting with
fluorescein isothiocyanate–conjugated anti-CD271 antibody (Miltenyi Biotec) and analyzed
with a FACSCalibur flow cytometer (BD Biosciences) and FlowJo software (TreeStar).
In vitro activation of cells with anti-CD3 and anti-CD28 antibodies
Jurkat cells were cultured at 1.5 × 106 cells/ml in six-well plates or 10-cm dishes in the
presence of doxycycline (1 µg/ml) for 22 hours to induce the production of FLAG-tagged c-
Rel. Cells were stimulated for the times indicated in the figure legends with plate-bound
anti-CD3 and anti-CD28 antibodies (each at 2 µg/ml).
Immunoprecipitations and Western blotting
Total cell lysates were prepared, and immunoprecipitations and Western blotting analysis
were performed as described previously (54).
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Quantitative real-time PCR analysis
DNA-free RNA and cDNA were prepared as previously described (54). Quantitative real-
time PCR with cDNA corresponding to 20 to 60 ng of total RNA and TaqMan Gene
Expression Assays (Applied Biosystems) was performed in a real-time PCR machine
(Realplex, Eppendorf). The expression of individual genes of interest was normalized to the
expression of the gene encoding the TFRC for human genes and UBE2D2 for mouse genes.
Electrophoretic mobility shift assays
Nuclear protein extracts were prepared as described previously (57). Nuclear extracts
corresponding to 4 to 7 µg of protein were tested for DNA binding with probes containing
the c-Rel–binding region of CD28RE and the p65-binding region of IL2. The OCT1 probe
was used as an internal control for normalization of the nuclear extracts. In the probe
containing the CD28RE-NF-IL2B AP-1 region, the AP-1–binding site was mutated as
previously described to restrict protein binding to only the CD28RE site in our assays (33).
Primer sequences are as follows. CD28RE-AP mutant probe: forward, 5′-
tcgagTTTAAAGAAATTCCAAATCAACATCAg; reverse, 5′-
tcgacTGATGTTGATTTGGAATTTCTTTAAAc; the c-Rel–binding site is shown in bold
and is underlined. CD28RE mutant-AP mutant probe: forward, 5′-
tcgagTTTAAAGACCTCGAAAAGCAACATCAg; reverse, 5′-
tcgacTGATGTTGCTTTTCGAGGTCTTTAAAc. IL2-κB probe: forward, 5′-
CCAAGAGGGATTTCACTAAATCC; reverse, 5′-
GGATTTAGGTGAAATCCCTCTTGG; the p65-binding site is shown in bold and is
underlined. OCT1 probe: forward, 5′-TGTCGAATGCAAATCACTAGAA; reverse, 5′-
TTCTAGTGATTTGCATTCGACA. Lysates were incubated with [γ-32P]ATP–labeled
probe in binding buffer [10 mM tris-Cl (pH 7.5), 50 mM NaCl, 4% glycerol, 1 mM MgCl2,
0.1 mM EDTA, poly(I:C) (50 µg/ml), 50 µM PUGNAc, 0.1 mM dithiothreitol (DTT)] for 20
min at room temperature. Antibody supershift assays to identify the DNA binding of FLAG-
tagged c-Rel were performed on ice for 30 min with 1 µg of anti-FLAG antibody (M2).
Samples were treated with a 100-fold excess of unlabeled probe for competition to
determine the specificity of binding. Samples were resolved by electrophoresis through 5%
nondenaturing polyacrylamide gels and analyzed by autoradiography.
Oligonucleotide pulldown assays
Cells expressing wild-type or mutant c-Rel (40 × 106) were cultured overnight in RPMI
medium containing doxycycline (1 µg/ml) for 22 hours. Cells were then stimulated with
plate-bound anti-CD3 and anti-CD28 antibodies for 3 hours. Cytoplasmic extracts were
prepared as described previously (33). Nuclear extracts were prepared in lysis buffer [20
mM Hepes (pH 7.9), 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1 mM DTT, 50 µM
PUGNAc, 0.1% NP-40, with protease inhibitor cocktail] and diluted in the same buffer
without NaCl to reach a final concentration of 150 mM NaCl. Lysates containing about 200
µg of nuclear proteins were incubated with 10 µg of poly(I:C) and 1 µg of annealed
biotinylated oligonucleotides containing the CD28RE region at 4°C in a rotator.
Oligonucleotide sequences used were as follows: biotinylated forward, 5′-Biosg-
TCGAGTTTAAAGAAATTCCAAATCAACATCAG; reverse, 5′-
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TCGACTGATGTTGATTTGGAATTTCTTTAAAC. After 1 hour, streptavidin-agarose
beads were added to the mixture for an additional 3 hours. The beads were washed thrice in
buffer containing 250 mM NaCl and then were analyzed by Western blotting.
Statistical analysis
Statistical differences in gene expression were analyzed with a two-tailed Student’s unpaired
t test with Prism software (GraphPad). Data are presented as means ± SEM, unless
otherwise indicated.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. The NF-κB subunit c-Rel is modified by O-GlcNAcylation
(A) Ramos cells and Jurkat cells (50 × 106 each) were left untreated or were treated with 4
mM GlcNAc and 100 µM PUGNAc for 12 hours. Samples were subjected to
immunoprecipitation (IP) with an anti–c-Rel antibody and were analyzed by Western
blotting (WB) with an antibody against O-GlcNAc (RL2). (B) Jurkat cells were left
untreated or were treated with 100 µM PUGNAc for 12 hours and 30 mM glucose for 3
hours or with glucose alone. Samples were analyzed as described in (A). (C) Splenocytes
(75 × 106) from C57BL/6 mice were treated with 4 mM GlcNAc and 100 µM PUGNAc for
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8 hours, subjected to immunoprecipitation with antibodies against p65 or c-Rel, and
analyzed by Western blotting with antibodies against the indicated proteins. (D) Ramos cells
were treated with 4 mM GlcNAc and 100 µM PUGNAc for 12 hours and then were
subjected to immunoprecipitation with anti-p65 antibody. O-GlcNAcylation of the 75-kD
protein was detected with the anti–O-GlcNAc (RL2) antibody (left). The blot was
reincubated with antibodies against c-Rel and p65. c-Rel coimmunoprecipitated with p65
(middle). The p65 protein ran with a lower molecular mass than did the O-GlcNAcylated
protein and c-Rel (75 kD) (right). The white dashed line running across all three blots
indicates separation between c-Rel and p65. (E) Human PBMCs were activated with
phytohemagglutinin for 48 hours. EL4 cells (50 × 106) and HEK 293T cells (10 × 106) were
cultured overnight in medium containing 5 mM glucose. Cells were treated and analyzed as
described in (B). (F) Jurkat cells (30 × 106) and MEFs (10 × 106) were left untreated or were
treated as described in (B) and then were subjected to immunoprecipitation with
succinylated WGA (sWGA) to pull down O-GlcNAcylated proteins. Samples were analyzed
by Western blotting with antibodies against c-Rel and SP1, which was used as a positive
control for O-GlcNAcylation and sWGA immunoprecipitation. (G) Chemoenzymatic O-
GlcNAc detection assay. Jurkat cells (30 × 106) and Ramos cells (30 × 106) were left
untreated or were treated with 4 mM GlcNAc and 100 µM PUGNAc for 8 hours and then
were subjected to chemoenzymatic labeling and immunoprecipitation with anti–c-Rel
antibody. Samples were then analyzed by Western blotting as indicated. (H) Baculoviral
expression of c-Rel or p65 in insect cells in the absence or presence of OGT. Cell lysates
were subjected to immunoprecipitation with antibodies against c-Rel or p65 and then were
analyzed by Western blotting with an anti–O-GlcNAc antibody. Total cell lysates were
analyzed by Western blotting with anti–c-Rel and anti-p65 antibodies. (I) Reverse
immunoprecipitation of O-GlcNAcylated c-Rel. Jurkat cells were treated as described in
(A). Anti–O-GlcNAc immunoprecipitates were analyzed by Western blotting with anti–c-
Rel and anti-SP1 antibodies. Western blots in (A) through (I) are representative of three
independent experiments.
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Fig. 2. c-Rel is O-GlcNAcylated at Ser350
(A) Ramos cells (10 × 106) were cultured overnight in RPMI medium without glucose and
then were treated for 3 hours with 5 or 30 mM glucose and 100 µM PUGNAc. Cells were
lysed by boiling in buffer containing 1% SDS and complete protease inhibitor cocktail, and
100 µg of total protein was chemoenzymatically labeled with a 5-kD PEG mass tag and
analyzed by Western blotting with antibodies against c-Rel and p65. The PEG–c-Rel band
represents the O-GlcNAc–modified subpopulation of c-Rel. Data are representative of four
independent experiments. (B) Percentage of c-Rel O-GlcNAcylation. Data are means ± SEM
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from three independent experiments. **P < 0.01 comparing 30 to 5 mM. (C and D) CID-MS
site mapping of the O-GlcNAcylation of c-Rel. (C) Fragment ions were calculated and
assigned as unmodified by GlcNAc because of facile neutral loss of GlcNAc in CID except
where indicated by “#.” GlcNAc modification was localized to the N-terminal 18 amino acid
residues. (D) Digested c-Rel was derivatized by BEMAD with 2-AET and analyzed by
nanoLCMS with CID. The methionine in both spectrums (bold) is oxidized. (E) HEK 293T
cells were transfected with plasmids encoding myc-tagged wild-type (WT) c-Rel or the
indicated c-Rel mutants. Cells were cultured overnight in medium containing 5 mM glucose.
Twenty-four hours after transfection, cells were treated with 30 mM glucose and 100 µM
PUGNAc for 3 hours, subjected to immunoprecipitation with anti-myc antibody, and
analyzed by Western blotting with antibodies against the indicated proteins. (F)
Representation of the structure of c-Rel. RHD, Rel homology domain; NLS, nuclear
localization signal; RID, Rel inhibitory domain; TAD, transactivation domain; P,
phosphorylation sites. (G) Sequences of human and mouse c-Rel with the O-GlcNAcylation
site indicated. (H) HEK 293T cells were transfected with plasmids encoding FLAG-tagged
WT or S350A mutant c-Rel. Cell lysates were subjected to immunoprecipitation with an
anti-OGT antibody or with rabbit immunoglobulin G (IgG) as a negative control, and
samples were analyzed by Western blotting with antibodies against the FLAG tag or OGT.
Total lysates were also analyzed by Western blotting with the same antibodies. (I) HEK
293T cells were transfected with plasmids encoding the indicated constructs. Cell lysates
were subjected to immunoprecipitation with anti-myc antibody and were analyzed by
Western blotting with an anti-FLAG antibody to examine c-Rel dimer formation. Total
lysates (TL) were also analyzed by Western blotting with anti-FLAG antibody. Western
blotting data in (E), (H), and (I) are representative of three independent experiments.
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Fig. 3. Mutating the O-GlcNAcylation site blocks the activity, but not the phosphorylation, of c-
Rel
(A) HEK 293T cells were transfected with plasmid encoding myc-tagged WT c-Rel together
with the indicated luciferase reporter plasmids. Luciferase activity was assessed with a dual
luciferase assay system. **P < 0.01 for the CD28RE reporter compared to the Ig-κB or
IL12-p40 reporters. (B and C) Jurkat cells were transfected with plasmids encoding myc-
tagged WT c-Rel or the S350Amutant c-Rel together with the CD28RE luciferase reporter
plasmid (Luc). (C) Twenty-four hours after transfection, cells were stimulated with anti-
CD3 and anti-CD28 antibodies for 4 hours. (B and C) Luciferase activity was assessed as
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described in (A). **P < 0.01, when comparing the S350A mutant c-Rel to WT c-Rel. (A to
C) Data in the bar graphs are means ± SEM of three independent experiments. Bottom:
Western blotting analysis of total cell lysates with antibodies against the myc tag or
phospholipase C-γ (PLC-γ). Blots are representative of three independent experiments. (D)
shRNA-mediated knockdown of endogenous c-Rel in Jurkat T-REx cells. Bottom:
Densitometric quantification of c-Rel amounts relative to those of actin. Data are means ±
SEM from three independent experiments; the Western blots are from one representative
experiment. ***P < 0.001. (E) Jurkat T-REx cells were treated with PMA (50 ng/ml) and
ionomycin (250 ng/ml) for 16 hours, and the amounts of IL-2 secreted into the culture
medium were determined by enzyme-linked immunosorbent assay (ELISA). Data are means
± SEM from three independent experiments. ***P < 0.001. (F) Jurkat T-REx cell clones
were treated with doxycycline (1 µg/ml) for 22 hours, and the production of WT and mutant
c-Rel was determined by Western blotting analysis with an anti-FLAG antibody. PLC-γ was
used as a loading control. (G) Jurkat T-REx cells (75 × 106) expressing WT and mutant c-
Rel were incubated with doxycycline, then treated as described in Fig. 1B, and subjected to
immunoprecipitation and Western blotting analysis with antibodies against the indicated
proteins. (H) Cellular phosphorylation of WT and S350A mutant c-Rel. FLAG-tagged c-Rel
proteins were immunoprecipitated from 75 × 106 Jurkat T-REx cells and analyzed by
autoradiography (top) and Western blotting (bottom). Data in (F) to (H) are representative of
three independent experiments.
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Fig. 4. Mutation of the O-GlcNAcylation site of c-Rel does not affect its nuclear translocation but
impairs its binding to the CD28RE
(A) Jurkat T-REx cell clones were treated with doxycycline for 22 hours to induce
production of WT c-Rel or S350A mutant c-Rel and then were left untreated or were treated
with anti-CD3 and anti-CD28 antibodies for 3 hours. Cytoplasmic and nuclear extracts were
analyzed with antibodies against the indicated proteins. PLC-γ and SP1 were used as loading
controls for the cytoplasmic and nuclear fractions, respectively. (B) Jurkat T-REx cell clones
were treated with doxycycline for 22 hours to induce production of WT or mutant c-Rel and
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then were left untreated or were treated with PMA and ionomycin for the indicated times.
Cytoplasmic and nuclear extracts were analyzed with antibodies against the indicated
proteins. (C) Jurkat T-REx cells (75 × 106) expressing WT c-Rel were treated as described
in (A). PUGNAc (100 µM) was added during the last 12 hours of doxycycline treatment.
FLAG-tagged c-Rel was immunoprecipitated from cytoplasmic and nuclear extracts, and
samples were analyzed by Western blotting with anti–O-GlcNAc and anti-FLAG antibodies.
(D) Jurkat T-REx cell clones expressing WT c-Rel or mutant c-Rel were treated as described
in (A), and nuclear extracts were analyzed by EMSA for binding to a CD28RE probe. OCT1
was used as a control for normalization of the nuclear extracts, and its specificity was
determined by competition with unlabeled OCT1 probe. Bottom: Western blotting analysis
of the input amounts of FLAG-tagged WT and mutant c-Rel. (E) Nuclear extracts from the
samples shown in (D) were incubated with a mutated CD28RE probe as a specificity control
for binding. (F) Jurkat T-REx cells expressing WT c-Rel were treated overnight with 50 µM
DON. Other treatments and EMSA analyses were performed as described in (D). (G) Cells
were treated overnight with 100 µM PUGNAc in culture medium containing 5 mM glucose.
Other treatments and EMSA analyses were performed as described in (D). (H) Cells were
treated as described in (D), and binding to the IL2-κB probe was examined by EMSA. (I) In
vitro oligonucleotide binding assay. Top: Binding of WT and mutant c-Rel to the CD28RE
probe. Bottom: Amounts of the respective proteins in the samples. Data in (A) to (I) are
representative of three to five independent experiments. PLC-γ, lamin, and SP1 were used as
loading controls.
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Fig. 5. O-GlcNAcylation of c-Rel is required for TCR-induced, CD28RE-dependent gene
expression
(A and B) PUGNAc increases anti-CD3– and anti-CD28–induced, c-Rel–dependent gene
expression in Jurkat cells. Cells were treated with 100 µM PUGNAc for 12 hours and then
were treated with plate-bound anti-CD3 and anti-CD28 antibodies (each at 2 µg/ml) for 3
hours. Samples were then analyzed by quantitative real-time polymerase chain reaction
(PCR) to determine the abundances of (A) IL2 and (B) CSF2 mRNAs relative to that of
transferrin receptor (TFRC) mRNA. **P < 0.01, ***P < 0.001, when comparing PUGNAc-
treated to untreated samples. (C to G) Jurkat T-REx cell clones were incubated with
doxycycline for 22 hours to induce production of WT c-Rel or S350A mutant c-Rel, left
untreated or treated with PUGNAc overnight, and then were left untreated or were treated
with anti-CD3 and anti-CD28 antibodies for 3 hours. Samples were then analyzed by
quantitative real-time PCR to determine the abundances of (C) IL2, (D) CSF2, (E) IFNG, (F)
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NFKBIA, and (G) TNFAIP3 mRNAs relative to that of TFRC mRNA. **P < 0.01, ***P <
0.001, when comparing cells expressing WT and mutant c-Rel under similar treatments. ns,
not significant. (H) Jurkat T-REx cell clones expressing WT c-Rel or mutant c-Rel were
treated overnight with 2 mM STZ and then were treated as described in (C). ***P < 0.001,
when comparing STZ-treated samples to untreated samples. Data in (A) to (H) are means ±
SEM of triplicate samples and are representative of three independent experiments, with
similar results.
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Fig. 6. TNF-induced gene expression and c-Rel activation are independent of c-Rel O-
GlcNAcylation
(A to D) Jurkat T-REx cell clones were incubated with doxycycline for 22 hours to induce
production of WT c-Rel or mutant c-Rel, left untreated or treated with PUGNAc overnight,
and then were left untreated or were treated with TNF (100 ng/ml) for 3 hours. Samples
were then analyzed by quantitative real-time PCR to determine the abundances of (A)
NFKBIA, (B) TNFAIP3, (C) IL2, and (D) CSF2 mRNAs relative to that of TFRC mRNA.
Data are means ± SEM of triplicate samples and are representative of three independent
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experiments with similar results. ns, not significant. (E) Increased O-GlcNAcylation does
not affect TNF-dependent c-Rel activation, but decreases p65 activation. Jurkat cells (30 ×
106) were cultured overnight in medium containing 5 mM glucose and were treated with 100
µM PUGNAc as indicated. Cells were then treated with 4 mM GlcNAc and 30 mM glucose
for 3 hours, and TNF was applied for the last 20 min of the treatment. Cytoplasmic and
nuclear extracts were prepared, subjected to immunoprecipitation with antibodies against c-
Rel, and then analyzed by Western blotting with antibodies specific for O-GlcNAc and c-
Rel. Data are representative of three independent experiments. Western blotting analysis of
p105 abundance confirmed uniform loading. Bottom: Densitometric quantification of the
amount of nuclear p65 relative to that of p105 after 20 min of stimulation with TNF. Data
are means ± SEM from three independent experiments. ***P < 0.001, when comparing
PUGNAc-treated to control samples. (F) Jurkat cells (40 × 106) were cultured overnight in
medium containing 5 mM glucose and then were treated with 4 mM GlcNAc and 30 mM
glucose in the absence or presence of PUGNAc for 3 hours. TNF was applied for the last 20
min of the treatment. Cytoplasmic and nuclear extracts were prepared, subjected to
immunoprecipitation with antibody against c-Rel, and analyzed by Western blotting with
antibodies specific for O-GlcNAc and c-Rel. Blots in (E) and (F) are representative of three
independent experiments. (G) Hypothetical schematic models of the regulation of the DNA
binding and transactivation functions of c-Rel by O-GlcNAcylation. (i) Stimulation of the
TCR induces the O-GlcNAcylation of c-Rel at Ser350, the binding of c-Rel to target DNA,
and the induction of gene expression. (ii) The S350A mutation blocks the TCR-induced
binding of c-Rel to DNA and inhibits gene expression. (iii and iv) The S350A mutation of c-
Rel has no effect on TNF-induced gene expression.
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